Adamis Pharmaceuticals (NASDAQ:ADMP) has been assigned a $10.00 price target by stock analysts at Maxim Group in a note issued to investors on Friday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Maxim Group’s price objective would indicate a potential upside of 258.42% from the stock’s previous close.

A number of other research firms have also weighed in on ADMP. HC Wainwright set a $7.00 price target on Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, September 28th. Zacks Investment Research upgraded Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 23rd. Finally, B. Riley downgraded Adamis Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $7.50 to $2.50 in a research report on Monday, November 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $6.20.

ADMP stock opened at $2.79 on Friday. The stock has a market cap of $133.83 million, a price-to-earnings ratio of -3.10 and a beta of 0.71. Adamis Pharmaceuticals has a twelve month low of $2.20 and a twelve month high of $5.10.

Several institutional investors and hedge funds have recently modified their holdings of the company. First Manhattan Co. bought a new stake in shares of Adamis Pharmaceuticals during the 3rd quarter valued at about $11,967,000. Vanguard Group Inc. boosted its position in shares of Adamis Pharmaceuticals by 27.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,637,513 shares of the specialty pharmaceutical company’s stock valued at $5,731,000 after acquiring an additional 348,645 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its position in shares of Adamis Pharmaceuticals by 71.4% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 1,200,000 shares of the specialty pharmaceutical company’s stock valued at $3,360,000 after acquiring an additional 500,000 shares during the last quarter. BlackRock Inc. boosted its position in shares of Adamis Pharmaceuticals by 203.2% during the 3rd quarter. BlackRock Inc. now owns 889,440 shares of the specialty pharmaceutical company’s stock valued at $3,113,000 after acquiring an additional 596,112 shares during the last quarter. Finally, Perceptive Advisors LLC bought a new stake in shares of Adamis Pharmaceuticals during the 3rd quarter valued at about $481,000. Hedge funds and other institutional investors own 22.37% of the company’s stock.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Further Reading: What are no-load funds?

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.